In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $19.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Ear is a 3-star analyst with an average return of 3.2% and a 41.03% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Revance Therapeutics, and Sarepta Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $25.22 average price target.
ACAD market cap is currently $3.16B and has a P/E ratio of 24.60.
Read More on ACAD:
- Promising Growth Trajectory and Strategic Investments Drive Buy Rating for ACADIA Pharmaceuticals
- Acadia Pharmaceuticals Reports Strong 2024 Financial Results
- ACADIA Pharmaceuticals: Strong Financial Performance and Growth Prospects Justify Buy Rating
- Acadia Pharmaceuticals reports Q4 EPS 86c, consensus 22c
- Acadia Pharmaceuticals sees FY25 revenue $1.03B-$1.095B, consensus $1.05B
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue